Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
Date:10/27/2011

THE WOODLANDS, Texas, Oct. 27, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its third quarter 2011 financial results on Tuesday, November 1, 2011 before the financial markets open.  Lexicon management will hold a conference call to discuss program status and financial results for the quarter at 11:00 a.m. Eastern Time that same day.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 20122666.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the conference call will be available on Lexicon's corporate website through November 29, 2011.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
2. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
4. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
5. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
6. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
8. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
9. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
10. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
11. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... E.I. Medical Imaging (EIMI) has partnered with ... design the worlds first ultrasound system to be used underwater ... habitat. In preparation for a piece produced by Icon ... Dr. Guttridge approached EIMI with the idea of an underwater ... sharks underwater. EIMI ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 The ... treat rare nervous system diseases, has concluded a worldwide license ... the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing ... in a Phase 2 study conducted in Europe ... the United States ...
Breaking Medicine Technology:
(Date:8/22/2017)... Denver, CO. (PRWEB) , ... August 22, 2017 , ... Each of the past six ... to take attractive pictures of these labels and stickers, demonstrating the variety and creativity of ... great group of label images came in. Now, it's time to announce the winners of ...
(Date:8/22/2017)... ... ... “Wilderness Voices”: a collection of poetry inspired by life on a Kentucky farm and ... Martha McKown, an ordained United Methodist minister with graduate degrees in Religious Education and ... sisters studied High School literature. She loved the early English folk ballads, especially ...
(Date:8/22/2017)... KS (PRWEB) , ... August 22, 2017 , ... TopConsumerReviews.com ... products to fight Fatigue . , As the stress of modern life continually ... up the pace. Constant use of artificial stimulants can trap people in vicious high/low ...
(Date:8/21/2017)... ... August 22, 2017 , ... ... Stevens as a 2017-2018 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting more than ...
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon running has surged ... country. , Outdoor running increases exposure to ultraviolet radiation, a carcinogen that promotes ... melanoma, and only half may be adequately protecting themselves with proper clothing and ...
Breaking Medicine News(10 mins):